Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
211. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
27-05-2024 |
View |
212. |
ECCT/21/02/03 | VAC078 A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria. |
Principal Investigator(s) 1. Mainga Patience Mayeso Hamaluba 2. Jean Bosco Ouedraogo 3. Halidou Tinto 4. Alassane Dicko 5. Ally Olotu Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
02-04-2021 |
View |
213. |
ECCT/24/06/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jesse Gitaka Site(s) in Kenya 1. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 2. Clinical Research Health Network (CREA-N) (Machakos county) 3. KEMRI-Mtwapa Clinical Annex (Kilifi county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
25-11-2024 |
View |
214. |
ECCT/24/08/03 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Mary Inziani Matilu Site(s) in Kenya 1. KEMRI-Mtwapa Clinical Annex (Kilifi county) 2. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 3. Clinical Research Health Network (CREA-N) (Machakos county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
21-12-2024 |
View |
215. |
ECCT/24/09/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Teresa Kinyari Site(s) in Kenya 1. University of Nairobi Clinical Research Centre (Nairobi City county) 2. KEMRI-Mtwapa Clinical Annex (Kilifi county) 3. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 4. Clinical Research Health Network (CREA-N) (Machakos county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
13-11-2024 |
View |
216. |
ECCT/20/07/03 | STAND A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND) |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. CREATES Strathmore University (Nairobi City county) 2. Getrudes Childrens Hospital (Nairobi City county) 3. International Cancer Institute (Elgeyo/Marakwet county) |
30-11-2020 |
View |
217. |
ECCT/20/10/04 | yellow fever vaccine CVIA 079 A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079. |
Principal Investigator(s) 1. Dr. Deborah Langat Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
28-12-2020 |
View |
218. |
ECCT/23/02/06 | BOHEMIA Safety and Efficacy A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya. |
Principal Investigator(s) 1. Marta Ferreira Maia 2. Joseph Mwangangi Site(s) in Kenya Kwale county, subcounties Lungalunga and Msambweni |
25-06-2023 |
View |
219. |
ECCT/13/08/01 | M72/AS01 E A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidatetuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults aged 18-50 years, living in a TB endemic region. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya KEMRI-CDC |
06-08-2013 |
View |
220. |
ECCT/23/05/02 | A5384 A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
12-10-2023 |
View |